Research graph
References from Immunogenicity and Safety of Co-administration of Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine With 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: A Randomized, Non-inferiority Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Differences between RSV A and RSV B subgroups and implications for pharmaceutical preventive measures
10.1007/s40121-024-01012-2 · 2024 · External reference
Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis
10.1111/irv.13031 · 2023 · External reference
Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study
10.1007/s40121-023-00792-3 · 2023 · External reference
Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study
10.1186/s12879-018-3002-3 · 2018 · External reference
Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation
2023 · External reference
Unresolved reference
External reference
Respiratory syncytial virus: a WAidid consensus document on new preventive options
10.3390/vaccines12121317 · 2024 · External reference
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial
10.1016/s2213-2600(25)00048-7 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Pneumococcal disease burden in high-risk older adults: exploring impact of comorbidities, long-term care facilities, antibiotic resistance, and immunization policies through a narrative literature review
10.1080/21645515.2024.2429235 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Immunogenicity, reactogenicity, and safety of AS01E-adjuvanted RSV prefusion F protein-based candidate vaccine (RSVPreF3 OA) when co-administered with a seasonal quadrivalent influenza vaccine in older adults: results of a phase 3, open-label, randomized controlled trial
10.1093/cid/ciad786 · 2026 · External reference
Safety and immunogenicity of respiratory syncytial virus prefusion F protein vaccine when co-administered with adjuvanted seasonal quadrivalent influenza vaccine in older adults: a phase 3 randomized trial
10.1093/cid/ciae365 · 2024 · External reference
Unresolved reference
External reference
Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: a systematic review and meta-analysis
10.1016/j.vaccine.2025.127293 · 2025 · External reference
Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged >/=18 years
10.1093/cid/ciab990 · 2022 · External reference
Pneumococcal serotype distribution and coverage of existing and pipeline pneumococcal vaccines
10.1093/infdis/jiaf376 · 2025 · External reference
Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules
10.1586/erv.11.142 · 2011 · External reference
Glycoconjugate vaccines and immune interference: a review
10.1016/j.vaccine.2010.06.026 · 2010 · External reference
Interactions of conjugate vaccines and co-administered vaccines
10.1080/21645515.2015.1091908 · 2016 · External reference
Adult vaccine coadministration is safe, effective, and acceptable: results of a survey of the literature
10.1111/irv.70090 · 2025 · External reference
